Incorporating mutations and bone marrow fibrosis into the revised international prognostic scoring system in myelodysplastic syndromes

References

• Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358–1374. doi:10.1056/NEJMra1904794
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. doi:10.1182/blood-2012-03-420489
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754–762. doi:10.1200/JCO.2008.18.2246
   PubMed Web of Science ®Google Scholar
• Fu B, Ok CY, Goswami M, et al. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol. 2013;92(10):1335–1343. doi:10.1007/s00277-013-1776-3
   PubMed Web of Science ®Google Scholar
• Buesche G, Teoman H, Wilczak W, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2008;22(2):313–322. doi:10.1038/sj.leu.2405030
   PubMed Web of Science ®Google Scholar
• Fu B, Jaso JM, Sargent RL, et al. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol. 2014;27(5):681–689. doi:10.1038/modpathol.2013.187
   PubMed Web of Science ®Google Scholar
• Scott BL, Storer BE, Greene JE, et al. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant. 2007;13(3):345–354. doi:10.1016/j.bbmt.2006.10.030
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Q, Zhang H, et al. Moderate to severe marrow fibrosis as a more advanced risk factor for MDS and MDS-AML patients with excess of blasts receiving allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021;27(8):666.e661–666.e669.
   Google Scholar
• Zhao Y, Guo J, Zhao S, et al. Bone marrow fibrosis at diagnosis and during the course of disease is associated with TP53 mutations and adverse prognosis in primary myelodysplastic syndrome. Cancers (Basel). 2022;14(12):2984. doi:10.3390/cancers14122984
   Web of Science ®Google Scholar
• Hou HA, Tsai CH, Lin CC, et al. Incorporation of mutations in five genes in the revised international prognostic scoring system can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer J. 2018;8(4):39. doi:10.1038/s41408-018-0074-7
   PubMedGoogle Scholar
• Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. Leukemia. 2016;30(11):2214–2220. doi:10.1038/leu.2016.138
   PubMed Web of Science ®Google Scholar
• Nazha A, Al-Issa K, Hamilton BK, et al. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. Leukemia. 2017;31(12):2848–2850. doi:10.1038/leu.2017.266
   PubMed Web of Science ®Google Scholar
• Loghavi S, Al-Ibraheemi A, Zuo Z, et al. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015;171(1):91–99. doi:10.1111/bjh.13529
   PubMed Web of Science ®Google Scholar
• Melody M, Al Ali N, Zhang L, et al. Decoding bone marrow fibrosis in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2020;20(5):324–328. doi:10.1016/j.clml.2020.01.003
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–1132.
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• Li B, Liu J, Jia Y, et al. Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes. Genes Chromosomes Cancer. 2018;57(2):80–88. doi:10.1002/gcc.22510
   PubMed Web of Science ®Google Scholar
• Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578–3584. doi:10.1182/blood-2011-12-399337
   PubMed Web of Science ®Google Scholar
• Wu K, Nie B, Li L, et al. Bioinformatics analysis of high frequency mutations in myelodysplastic syndrome-related patients. Ann Transl Med. 2021;9(19):1491–1491. doi:10.21037/atm-21-4094
   PubMed Web of Science ®Google Scholar
• Kang MG, Kim HR, Seo BY, et al. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts. BMC Cancer. 2015;15(1):484. doi:10.1186/s12885-015-1493-5
   PubMedGoogle Scholar
• Tefferi A, Lasho TL, Patnaik MM, et al. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. Am J Hematol. 2017;92(12):1311–1317. doi:10.1002/ajh.24901
   PubMed Web of Science ®Google Scholar
• Wu SJ, Tang JL, Lin CT, et al. Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. Am J Hematol. 2013;88(11):E277–282.
   PubMed Web of Science ®Google Scholar
• Wang H, Guo Y, Dong Z, et al. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome. Sci Rep. 2020;10(1):18622. doi:10.1038/s41598-020-74744-z
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim K, Hwang B, et al. The high frequency of the U2AF1 S34Y mutation and its association with isolated trisomy 8 in myelodysplastic syndrome in asians, but not in caucasians. Leuk Res. 2017;61:96–103. doi:10.1016/j.leukres.2017.09.001
   PubMed Web of Science ®Google Scholar
• Tefferi A, Mudireddy M, Finke CM, et al. U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. Am J Hematol. 2018;93(6):E146–e148.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Gangat N, Pardanani A, et al. Myelofibrosis: genetic characteristics and the emerging therapeutic landscape. Cancer Res. 2022;82(5):749–763. doi:10.1158/0008-5472.CAN-21-2930
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang N, Wu X, et al. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis. Ann Hematol. 2019;98(12):2629–2639. doi:10.1007/s00277-019-03843-3
   PubMed Web of Science ®Google Scholar
• Nazha A. The MDS genomics-prognosis symbiosis. Hematology Am Soc Hematol Educ Program. 2018;2018(1):270–276. doi:10.1182/asheducation-2018.1.270
   PubMedGoogle Scholar